Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial (SDHD), also known as CybS or complex II subunit D, is an essential nuclear-encoded transmembrane protein that anchors the four-subunit succinate dehydrogenase (Complex II) complex to the inner mitochondrial membrane. SDHD, together with SDHC, forms the hydrophobic membrane-anchoring domain containing the ubiquinone-binding pocket (Q-site) and a heme b group, which are critical for transferring electrons from succinate (via SDHA and SDHB) to ubiquinone in the mitochondrial electron transport chain. This dual role directly links the tricarboxylic acid (TCA) cycle to oxidative phosphorylation. Mutations in the SDHD gene disrupt mitochondrial energy metabolism and are strongly implicated in hereditary paraganglioma-pheochromocytoma syndrome (PGL-PCC), gastrointestinal stromal tumors (GISTs), and other SDH-deficient cancers, where the resulting accumulation of succinate acts as an oncometabolite that stabilizes hypoxia-inducible factor 1-alpha (HIF-1α). Conversely, pharmacologic inhibition of SDHD and the wider Complex II has emerged as a therapeutic strategy in oncology and cardiology. Small molecules such as lonidamine, alpha-tocopheryl succinate (α-TOS), and the highly potent experimental tool atpenin A5 target the ubiquinone-binding site of SDHD/SDHC, blocking electron flow to trigger reactive oxygen species (ROS) generation and selective apoptosis in cancer cells. Additionally, competitive inhibitors like malonate are being investigated for cardioprotection during ischemia-reperfusion injury by preventing rapid succinate oxidation and subsequent ROS bursts.
Inhibition of the ubiquinone-binding (Q-site) pocket of mitochondrial complex II, blocking electron transfer from succinate to ubiquinone, which leads to accumulation of succinate, generation of reactive oxygen species (ROS), and induction of apoptosis.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial (SDHD).